22nd International AIDS Conference

23-27 July 2018 
Amsterdam, the Netherlands

The International AIDS Conference brings together science, leadership, and community to advance treatment and prevention of HIV. 

 

You can find DNDi in the Exhibition Hall at Booth #215!

DNDi @ AIDS 2018

Side Event

Flyer Side Event AIDS Conference

Diagnose, Treat, Innovate: A paradigm shift for ending paediatric AIDS

Co-organized by the African Society for Laboratory Medicine (ASLM), the Clinton Health Access Initiative (CHAI), DNDi, Elizabeth Glaser Pediatrics AIDS Foundation, and Unitaid

Date: Monday, 23 July 2018
Time: 12:30-14:30
Venue: Hall 11B

Speakers:

  • Smiljka de Lussigny, Programme Manager HIV and HCV diagnostics, Unitaid
  • Ndlovu Nqobile, Project Director, ASLM
  • Trevor Peter, Senior Scientific Director Diagnostics, CHAI
  • Rebecca Bailey, Associate Director, Point-of-Care Early Infant Diagnosis Project, Elizabeth Glaser Pediatrics AIDS Foundation
  • Victor Musiime, Senior Lecturer at Makerere University, College of Health Sciences, Department of Paediatrics and Child Health, Uganda
  • Chewe Luo, Chief of HIV/AIDS, Programme Division, UNICEF
  • George Siberry, Director for HIV Treatment, Care & TB, Senior Pediatric Technical Advisor, PEPFAR
  • Surbhi Modi, Chief, Maternal and Child Health Branch, Centers for Disease Control and Prevention

RSVP: amataka@aslm.org

 

Session

ART in infants and children

Date: Wednesday, 25 July 2018
Time: 14:30-16:00
Venue: Hall 10

Pellet formulation of lopinavir/ritonavir in children: 48-week evolution of viral suppression across age categories in the LIVING study
Andrieux-Meyer I, Salami OOmollo R, Musiime V, Wamalwa D*, Maleche Obimbo E, Kekitiinwa A, Mwanga-Amumpaire J, Oyaro P, Bukusi EA, Waweru MWasunna MLee JSimon F, Lallemant M, for the LIVING STUDY GROUP

*Presenting author

 

Poster Discussion

Antiretrovirals: Pharmacokinetics and generics

Date: Wednesday, 25 July 2018
Time: 13:00-14:00
Venue: Emerald Room 

TB/HIV co-treatment with super-boosted lopinavir and anti-tuberculosis treatment lowers abacavir concentration in children 
Rabie H, Tikiso T*, McIlleron H, Lee J, Andrieux-Meyer I, Cotton M, Lallemant M, Denti P

*Presenting author

 

Poster

Whether and why caregivers adhere to oral lopinavir/ritonavir pellets: lessons for scaling up an innovative pediatric HIV treatment in Kenya
Nöstlinger C*, Nebot Giralt A, Ouma O, Nyamongo I, Salami O, Lallemant M, Lee J, Marchal B

*Presenting author

 

Pre-Conference

10th Workshop on HIV Paediatrics

Date: 20-21 July 2018

Pellet formulation of lopinavir/ritonavir in children: 48-week evolution of viral suppression across age categories in the LIVING study
Andrieux-Meyer I, Salami O*Omollo R, Musiime V, Wamalwa D, Maleche Obimbo E, Kekitiinwa A, Mwanga-Amumpaire J, Oyaro P, Bukusi EA, Waweru MWasunna MLee JSimon F, Lallemant M, for the LIVING STUDY GROUP

*Presenting author

 

 

More information: